[go: up one dir, main page]

AR035534A1 - Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion - Google Patents

Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion

Info

Publication number
AR035534A1
AR035534A1 ARP020100289A ARP020100289A AR035534A1 AR 035534 A1 AR035534 A1 AR 035534A1 AR P020100289 A ARP020100289 A AR P020100289A AR P020100289 A ARP020100289 A AR P020100289A AR 035534 A1 AR035534 A1 AR 035534A1
Authority
AR
Argentina
Prior art keywords
seq
cell
plant
polyunsaturated fatty
vegetable
Prior art date
Application number
ARP020100289A
Other languages
English (en)
Inventor
Pradip Mukerji
Yung-Sheng Huang
Tapas Das
Jennifer Thurmond
Suzette L Pereira
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR035534A1 publication Critical patent/AR035534A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6431—Linoleic acids [18:2[n-6]]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)

Abstract

Secuencia de nucleótidos aislada, o fragmento, que comprende o que es complementaria en por lo menos un 50% aproximadamente de la secuencia de nucleótidos que comprende la SEQ ID N° 13, la SEQ ID N° 19 o la SEQ ID N° 28, SEQ ID N° 30, SEQ ID N° 32 o SEQ ID N° 34. Estas secuencias pueden codificar una desaturasa funcionalmente activa (proteína purificada) que utiliza un ácido graso poliinsaturado como sustrato. Las secuencias pueden derivar, de Saprolegnia diclina (SEQ ID N° 13 y SEQ ID N° 19), Thraustochytrium aureum (SEQ ID N° 28, SEQ ID N° 30 y SEQ ID N° 32) o de Isochysis galbana (SEQ ID N° 34). Además se incluyen las proteínas purificadas codificadas por las secuencias de nucleótidos a las que se hizo referencia previamente. Aún más, también se revela un método para producir una desaturasa. También se describe un vector que comprende la secuencia de nucleótidos representada en la SEQ ID N° 13, SEQ ID N° 19, SEQ ID N° 28, SEQ ID N° 30, SEQ ID N° 32 o SEQ ID N° 34 ligada operativamente a una secuencia promotora o reguladora. Una célula huésped, una célula de mamífero, una célula vegetal, una planta, un tejido vegetal o una planta transgénica que comprendan este vector, también se detallan así como los ácidos o aceites que se expresan. Además, se incluye un método para producir un ácido graso poliinsaturado así como una composición nutricional que comprende por lo menos un ácido graso poliinsaturado seleccionado del grupo formado por el producto de ácido graso poliinsaturado producido de acuerdo con los métodos descriptos previamente. Las desaturasas son criticas para la producción de ácidos grasos poliinsaturados de cadena larga (PUFA) que cumplen muchas funciones importantes como por ejemplo en la membrana plasmática de una célula, donde se encuentran en la forma de fosfolípidos. Resulta de interés aislar los genes involucrados en la síntesis de PUFA provenientes de especies que producen éstos ácidos grasos de forma natural y expresar dichos genes en un sistema microbiológico, vegetal o animal que pueda ser alterado para proveer la producción de cantidades comerciales de uno o varios PUFA.
ARP020100289A 2001-01-25 2002-01-25 Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion AR035534A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/769,863 US6635451B2 (en) 2001-01-25 2001-01-25 Desaturase genes and uses thereof
US10/054,534 US7067285B2 (en) 2001-01-25 2002-01-22 Desaturase genes and uses thereof

Publications (1)

Publication Number Publication Date
AR035534A1 true AR035534A1 (es) 2004-06-02

Family

ID=27735000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100289A AR035534A1 (es) 2001-01-25 2002-01-25 Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion

Country Status (8)

Country Link
US (6) US6635451B2 (es)
EP (2) EP2325300B1 (es)
JP (3) JP4347397B2 (es)
AR (1) AR035534A1 (es)
AT (1) ATE535602T1 (es)
CA (2) CA2699611C (es)
ES (1) ES2377198T3 (es)
PT (1) PT1392823E (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635451B2 (en) * 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
US20050089879A1 (en) * 2001-07-31 2005-04-28 Ivo Feussner Method for producing arachidonic acid in transgenic organisms
DE10219203A1 (de) * 2002-04-29 2003-11-13 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in Pflanzen
EP1619960A4 (en) * 2003-03-07 2009-03-18 Advanced Bionutrition Corp FEED FORMULATION FOR LAND AND WATER RESIDENTS
AR045290A1 (es) * 2003-08-21 2005-10-19 Monsanto Technology Llc Acido graso desaturasas de primula
EP2902021B1 (en) 2004-04-16 2018-11-14 Monsanto Technology LLC Expression of fatty acid desaturases in corn
AU2011232757B2 (en) * 2004-04-22 2013-10-03 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
US7807849B2 (en) 2004-04-22 2010-10-05 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
CA3023314C (en) 2004-04-22 2019-12-10 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
US7364883B2 (en) * 2004-05-07 2008-04-29 Yeastern Biotech Co., Ltd. Process for producing poly-unsaturated fatty acids by oleaginous yeasts
ATE479757T1 (de) * 2004-06-04 2010-09-15 Fluxome Sciences As Stoffwechseltechnisch hergestellte zellen zur produktion mehrfach ungesättigter fettsäuren
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US7550286B2 (en) * 2004-11-04 2009-06-23 E. I. Du Pont De Nemours And Company Docosahexaenoic acid producing strains of Yarrowia lipolytica
US7732680B2 (en) 2005-03-16 2010-06-08 Metabolix, Inc. Chemically inducible expression of biosynthetic pathways
JP5033122B2 (ja) 2005-05-23 2012-09-26 アルカディア バイオサイエンシズ，インコーポレイテッド 増量ガンマ−リノレン酸を含むベニバナ
ES2451667T3 (es) 2005-06-07 2014-03-28 Ocean Nutrition Canada Limited Microorganismos eucariotas para producir lípidos y antioxidantes
WO2007103738A2 (en) 2006-03-01 2007-09-13 Pioneer Hi-Bred International, Inc. Compositions related to the quantitative trait locus 6 (qtl6) in maize and methods of use
US7465793B2 (en) 2006-04-20 2008-12-16 E.I. Du Pont De Nemours And Company Synthetic Δ17 desaturase derived from Phytophthora ramourum and its use in making polyunsaturated fatty acids
JP5531324B2 (ja) * 2006-08-01 2014-06-25 ディーエスエム ニュートリショナル プロダクツ アーゲー 油生産微生物およびその改変方法
WO2008025068A1 (en) 2006-08-29 2008-03-06 Commonwealth Scientific And Industrial Research Organisation Synthesis of fatty acids
DK2087105T3 (da) * 2006-10-30 2015-05-26 Du Pont Delta 17-desaturase og anvendelse heraf ved fremstilling af flerumættede fedtsyrer
US8957280B2 (en) * 2007-05-03 2015-02-17 E. I. Du Pont De Nemours And Company Delta-5 desaturases and their use in making polyunsaturated fatty acids
CA2695161C (en) * 2007-07-13 2018-05-22 Ocean Nutrition Canada Limited D4 desaturases and d5 elongases
EP2304032A1 (en) * 2008-08-01 2011-04-06 E. I. du Pont de Nemours and Company 6 desaturases and their use in making polyunsaturated fatty acids
CN102317459A (zh) 2008-11-18 2012-01-11 联邦科学技术研究组织 产生ω-3脂肪酸的酶和方法
US8916154B2 (en) 2009-04-27 2014-12-23 Abbott Laboratories Antibodies against delta-5 desaturase and uses thereof
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
HUE033766T2 (en) 2012-06-15 2018-01-29 Commw Scient Ind Res Org Production of long chain polyunsaturated fatty acids in plant cells
ES2666895T3 (es) 2013-03-13 2018-05-08 Dsm Nutritional Products Ag Modificación genética de microorganismos
CA3241340A1 (en) 2013-12-18 2015-06-25 Grains Research And Development Corporation Lipid comprising long chain polyunsaturated fatty acids
WO2015195479A1 (en) * 2014-06-16 2015-12-23 Murphy Brown, Llc Method and system for in-line analysis of products
EP3160482A4 (en) 2014-06-27 2018-02-14 Commonwealth Scientific and Industrial Research Organisation Lipid comprising docosapentaenoic acid
CN112741154A (zh) * 2019-10-30 2021-05-04 东北农业大学 一种早产儿配方液态乳及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501692A (es) 1980-09-24 1982-09-16
DE3381518D1 (de) 1982-01-22 1990-06-07 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5420034A (en) * 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
US4943674A (en) * 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8524276D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5188958A (en) * 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5004863B2 (en) * 1986-12-03 2000-10-17 Agracetus Genetic engineering of cotton plants and lines
US5416011A (en) * 1988-07-22 1995-05-16 Monsanto Company Method for soybean transformation and regeneration
US5130242A (en) 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
CA1338683C (en) * 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
US5231020A (en) * 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5106739A (en) * 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5196198A (en) 1989-06-02 1993-03-23 Abbott Laboratories Parenteral nutrition product
US5175095A (en) * 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
DE69103753T3 (de) 1990-05-25 2008-01-24 E.I. Dupont De Nemours And Co., Wilmington Nukleotidsequenz des gens für stearoyl-acp-desaturase aus soja.
US5518908A (en) * 1991-09-23 1996-05-21 Monsanto Company Method of controlling insects
PH31293A (en) 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
DK0616644T3 (da) 1991-12-04 2003-10-27 Du Pont Fedtsyredesaturase-gener fra planter
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
AU5407594A (en) 1992-11-17 1994-06-08 E.I. Du Pont De Nemours And Company Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants
DE69424861T2 (de) * 1993-02-26 2000-12-28 Calgene Llc., Davis Geminivirus-basiertes-genexpressionsystem
JPH07228888A (ja) 1994-02-17 1995-08-29 Shimadzu Corp 高度不飽和脂肪酸の精製方法
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
NZ281041A (en) * 1994-03-09 1998-04-27 Abbott Lab Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
EP0749492A1 (en) 1994-03-09 1996-12-27 Abbott Laboratories Humanized milk
US5427857A (en) * 1994-06-28 1995-06-27 E. I. Du Pont De Nemours And Company Cathodic electrocoating compositions containing branched epoxy amine resins
US5631152A (en) * 1994-10-26 1997-05-20 Monsanto Company Rapid and efficient regeneration of transgenic plants
US5654402A (en) 1994-10-26 1997-08-05 Michigan State University Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase
JPH0913077A (ja) 1995-07-04 1997-01-14 Nisshin Oil Mills Ltd:The 臓器蓄積性の高い油脂
US5972664A (en) 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
SK139999A3 (en) * 1997-04-11 2000-05-16 Calgene Llc A nucleic acids construct, isolated nucleotide sequence, recombinant plant cell, method of biosynthesis of polyunsaturated long chain fatty acids, pharmaceutical, food and cosmetic preparation and use thereof
AU4544799A (en) 1998-05-29 1999-12-13 Ohio University Compositions and methods for the synthesis of fatty acids, their derivatives and downstream products
JP2000069987A (ja) 1998-08-28 2000-03-07 Suntory Ltd アラキドン酸含有脂質並びにジホモ−γ−リノレン酸含有脂質の製造方法
WO2000020603A1 (en) 1998-10-05 2000-04-13 Abbott Laboratories Altered fatty acid biosynthesis in insect cells using delta five desaturase
EP1035207A1 (en) 1999-03-09 2000-09-13 MultiGene Biotech GmbH cDNA molecules of the members of gene family encoding human fatty acid desaturases and their use in diagnosis and therapy
PL357415A1 (en) 1999-06-07 2004-07-26 Basf Plant Science Gmbh Delta6-acetylenase and delta6-desaturase from ceratodon purpureus
CN105483142A (zh) 2000-09-28 2016-04-13 生物源食物及科学公司 脂肪酸去饱和酶家族成员fad4、fad5、fad5-2和fad6及它们的应用
US6635451B2 (en) * 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
BR0205508A (pt) 2001-01-25 2005-05-03 Abbott Lab Genes para dessaturase e usos dos mesmos

Also Published As

Publication number Publication date
JP4347399B2 (ja) 2009-10-21
EP2333052A1 (en) 2011-06-15
JP2008289479A (ja) 2008-12-04
EP2325300A1 (en) 2011-05-25
US8143383B2 (en) 2012-03-27
US6635451B2 (en) 2003-10-21
US7241619B2 (en) 2007-07-10
JP4347400B2 (ja) 2009-10-21
JP2008289491A (ja) 2008-12-04
US20030190733A1 (en) 2003-10-09
US20030157144A1 (en) 2003-08-21
US20030167525A1 (en) 2003-09-04
US8143486B2 (en) 2012-03-27
CA2699611A1 (en) 2002-10-17
EP2333052B1 (en) 2013-10-09
ATE535602T1 (de) 2011-12-15
EP2325300B1 (en) 2013-11-06
US20090265798A1 (en) 2009-10-22
CA2698579C (en) 2013-12-10
US7067285B2 (en) 2006-06-27
ES2377198T3 (es) 2012-03-23
US20110003351A1 (en) 2011-01-06
US20110003360A1 (en) 2011-01-06
PT1392823E (pt) 2012-03-08
JP2008289490A (ja) 2008-12-04
CA2699611C (en) 2013-12-10
JP4347397B2 (ja) 2009-10-21
CA2698579A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
AR035534A1 (es) Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion
AU2018204726B2 (en) Production of dihydrosterculic acid and derivatives thereof
Miray et al. Molecular control of oil metabolism in the endosperm of seeds
US9222101B2 (en) Method of producing fatty acids or lipids containing fatty acids using thioesterase variants
Faure et al. Camelina, a Swiss knife for plant lipid biotechnology
RU2008149700A (ru) Дельта-5-десатураза и ее применение для получения полиненасыщенных жирных кислот
Wang et al. A lipid droplet-associated protein involved in lipid droplet biogenesis and triacylglycerol accumulation in the oleaginous microalga Phaeodactylum tricornutum
CA2435685A1 (en) Desaturase genes and uses thereof
JP6319889B2 (ja) アシル−ａｃｐチオエステラーゼ改変体を用いた脂質の製造方法
Chi et al. Fatty acid biosynthesis in eukaryotic photosynthetic microalgae: identification of a microsomal delta 12 desaturase in Chlamydomonas reinhardtii
JP2014527803A (ja) トリアシルグリセロール（ｔａｇ）リパーゼの遺伝子操作による微細藻類における脂質含量の増大
Yoshino et al. Production of ω3 fatty acids in marine cyanobacterium Synechococcus sp. strain NKBG 15041c via genetic engineering
RU2002108174A (ru) Ген дезатуразы кислоты жирного ряда из растений
Nawkarkar et al. Heterogeneous diacylglycerol acyltransferase expression enhances lipids and PUFA in Chlorella species
Yang et al. Functional characterization of Physcomitrella patens glycerol-3-phosphate acyltransferase 9 and an increase in seed oil content in Arabidopsis by its ectopic expression
AU2015356285A1 (en) Method of producing lipid using acyl-acp thioesterase
Chodok et al. Metabolic engineering and oil supplementation of Physcomitrella patens for activation of C22 polyunsaturated fatty acid production
Chenarani et al. Characterization of sucrose binding protein as a seed-specific promoter in transgenic tobacco Nicotiana tabacum L.
Huang et al. Cloning and functional identification of delta5 fatty acid desaturase gene and its 5′-upstream region from marine fungus Thraustochytrium sp. FJN-10
RU2011114558A (ru) Гены δ-8-десатуразы, ферменты, кодируемые ими, и их применение
Suhaimi et al. Expansion of omega-3 polyunsaturated fatty acid metabolism of the oleaginous diatom Fistulifera solaris by genetic engineering
Karthikeyan et al. Algal Biorefineries and the Circular Bioeconomy: Industrial Applications and Future Prospects
Sharma et al. Genetic engineering in improving the output of algal biorefinery
CN113412332A (zh) 用于在植物中产生高水平pufa的改进方法
CN112969792A (zh) 用于在植物中产生高水平pufa的改进方法

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure